Literature DB >> 22922884

PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.

Watcharin Loilome1, Sasithorn Yooyuen, Nisana Namwat, Paiboon Sithithaworn, Anucha Puapairoj, Junko Kano, Masayuki Noguchi, Masanao Miwa, Puangrat Yongvanit.   

Abstract

Cholangiocarcinoma (CCA) associated with Opisthorchis viverrini (Ov) chronic infection is the most frequent primary liver cancer in Thailand, and current approaches to early diagnosis and curative treatments are largely disappointing. We hypothesize a role for protein kinase A (PKA) in Ov-induced CCA. First, we studied the PKA isozyme switching in the liver from the hamster CCA model using quantitative (q) PCR, in situ hybridization, and immunohistochemical and western blot analysis. Second, the presence of extracellular PKA (ECPKA) in CCA cell lines and their conditioned media was demonstrated by western blot and PKA activity assay. Third, we determined the association between PRKAR1A expression and serum ECPKA autoantibody in patients with CCA by ELISA. We demonstrated that an increased PRKAR1A expression is restricted to the biliary cells starting from week 1, with remarkable up-regulation when CCA has completely developed by week 24. The switching of the PKA regulatory subunit isoforms from PRKAR2B/PKAII to PRKAR1A/PKAI is significantly associated with cholangiocyte proliferation. Further, we observed that human CCA cell lines express PRKAR1A but not PRKAR2B and excrete ECPKA. Finally, ECPKA autoantibodies are detected in serum of patients with CCA, adenocarcinoma, and Ov infection with periductal fibrosis, but not from Ov-infected subjects without periductal fibrosis lesion and healthy controls. We conclude that PKA isozyme switching and the PRKAR1A/PKAI pathway might contribute to the induction of cholangiocyte transformation and proliferation in Ov-induced CCA. Overexpression of PRKAR1A leads to secretion of ECPKA which is associated with serum autoantibody that may constitute a biomarker for human CCA genesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922884     DOI: 10.1007/s13277-012-0491-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis.

Authors:  N Batheja; A Suriawinata; R Saxena; G Ionescu; M Schwartz; S N Thung
Journal:  Mod Pathol       Date:  2000-12       Impact factor: 7.842

2.  Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker.

Authors:  Y S Cho; Y N Lee; Y S Cho-Chung
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

Review 3.  cAMP-dependent protein kinase: role in normal and malignant growth.

Authors:  Y S Cho-Chung; S Pepe; T Clair; A Budillon; M Nesterova
Journal:  Crit Rev Oncol Hematol       Date:  1995-11       Impact factor: 6.312

4.  Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133.

Authors:  G A Gonzalez; M R Montminy
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

Review 5.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.

Authors:  Y S Cho-Chung
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

6.  Protein A, avidin, and biotin in immunohistochemistry.

Authors:  S M Hsu; L Raine
Journal:  J Histochem Cytochem       Date:  1981-11       Impact factor: 2.479

7.  Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism.

Authors:  Meinhard Schiller; Frank Verrecchia; Alain Mauviel
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

8.  8-nitroguanine formation in the liver of hamsters infected with Opisthorchis viverrini.

Authors:  Somchai Pinlaor; Puangrat Yongvanit; Yusuke Hiraku; Ning Ma; Reiji Semba; Shinji Oikawa; Mariko Murata; Banchob Sripa; Paiboon Sithithaworn; Shosuke Kawanishi
Journal:  Biochem Biophys Res Commun       Date:  2003-09-26       Impact factor: 3.575

9.  A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.

Authors:  Nicolas Jonckheere; Michaël Perrais; Christophe Mariette; Surinder K Batra; Jean-Pierre Aubert; Pascal Pigny; Isabelle Van Seuningen
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

10.  Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa.

Authors:  A W Bradbury; D C Carter; W R Miller; Y S Cho-Chung; T Clair
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more
  4 in total

Review 1.  Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand.

Authors:  Masanao Miwa; Satoshi Honjo; Gyokukou You; Masakazu Tanaka; Kazuhiko Uchida; Petcharin Srivatanakul; Thiravud Khuhaprema; Watcharin Loilome; Anchalee Techasen; Chaisiri Wongkham; Temduang Limpaiboon; Puangrat Yongvanit; Sopit Wongkham
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

2.  Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma.

Authors:  Wassana Jamnongkan; Anchalee Techasen; Raynoo Thanan; Kunyarat Duenngai; Paiboon Sithithaworn; Eimorn Mairiang; Watcharin Loilome; Nisana Namwat; Chawalit Pairojkul; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2012-11-28

3.  Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma.

Authors:  Rucksak Rucksaken; Chawalit Pairojkul; Porntip Pinlaor; Narong Khuntikeo; Sittiruk Roytrakul; Carlo Selmi; Somchai Pinlaor
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

4.  The diagnostic value of extracellular protein kinase A (ECPKA) in serum for gastric and colorectal cancer.

Authors:  Yan Wu; Yafang Li; Junqiang Liu; Mengjiao Chen; Wei Li; Yongchang Chen; Min Xu
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.